Neo7logix is a biopathway HLA affinity mapping and selection prediction ranking device that combines biological intelligence programming (molecular mapping), knowledge-based systems applications, artificial intelligence and machine learning. The platform integration utilizes all NGS data including WES, WGS, RNAseq and Proteomics. Neo7logix, LLC proprietary architecture is applicable for cancer, autoimmune and neurodegenerative diseases. A precision mapping, ranking and selection profile is then generated to derive a precision-based personalized Immuno-molecular Augmentation therapeutic application that activates the immune system defenses and regulatory mechanisms to intelligently fight the cancer and / or disease process. Neo7logix, LLC can also predict "best fit" drug applications in many disease types. In this paper the focus profiling, mapping, affinity ranking and final selection is in a patient prototype sample lung cancer diagnosis.
pathways comprising personalized cancer model are shown on Figure   1 .
Neoantigen Selection
All proteins were ranked according to the following criteria to determine their relative importance for vaccine selection:
• Presence of mutation in both circulating tumor cells (CTCs) isolated from patient blood and in primary tumor 
Drug Recommendations Using Personalized Cancer Model
Besides cancer vaccine design we also recommended the following drugs for the patient based on his cancer model:
1) Endostatin because COL18A1 is mutated. COL18A1 is a proprotein for endogenous endostatin. Decrease of endostatin production in patient tumor is the mechanism of angiogenesis activation inside the tumor 2) EGFR inhibitors: axitinib, sorafenib, sunitinib, pazopanib Acetylation Table 4 . Peptides Selected For PBIMA SM All scores for protein ranking and for peptide ranking are shown as columns in the table.
Figure 1. Personalized Cancer Model
Protein node color:
• Red -mRNA expression is upregulated in tumor compared with normal lung 
